CW Advisors LLC Acquires 76,119 Shares of Gilead Sciences, Inc. $GILD

CW Advisors LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 309.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 100,734 shares of the biopharmaceutical company’s stock after acquiring an additional 76,119 shares during the quarter. CW Advisors LLC’s holdings in Gilead Sciences were worth $11,169,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in GILD. Activest Wealth Management lifted its holdings in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter worth $27,000. Putney Financial Group LLC lifted its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors boosted its holdings in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Truist Financial began coverage on Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective on the stock. The Goldman Sachs Group increased their target price on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, BMO Capital Markets set a $135.00 price target on Gilead Sciences in a report on Tuesday, November 25th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $130.65.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 135,757 shares of company stock worth $16,616,127 over the last three months. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 1.9%

Shares of GILD stock opened at $122.62 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm has a fifty day moving average of $120.76 and a 200-day moving average of $115.14. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The stock has a market cap of $152.13 billion, a price-to-earnings ratio of 19.01, a P/E/G ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.